{
    "nctId": "NCT00431795",
    "briefTitle": "Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer",
    "officialTitle": "A Multicenter Randomized Phase II Study of Second Line Chemotherapy With Epirubicin( Farmorubicin) Versus the Pegylated Liposomal Doxorubicin in Advanced Breast Cancer Patients",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Assessment of antitumor efficacy by objective tumor response rates",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18-75 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Adequate bone marrow function (Absolute neutrophil count \\>1000/mm\\^3, Platelet count\\>100000/mm\\^3, Hemoglobin\\>9gr/mm\\^3)\n* Histologically- or cytologically- confirmed breast adenocarcinoma\n* No prior anthracycline-based chemotherapy as treatment of advanced breast cancer\n* No prior chemotherapy with \u2265 300mg/m2 doxorubicin or \u2265 540mg/m2 epirubicin as adjuvant setting\n* At least 4 weeks interval since prior anticancer treatment\n* Measurable disease as defined by the presence of at least one measurable lesion(except bone metastases, ascites or pleural effusions)\n* Life expectancy \\> 3 months\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or nursing\n* Documented history of congestive heart failure (CHF), serious arrhythmia, or myocardial infarction (within 6 months)\n* Other invasive malignancy except nonmelanoma skin cancer or acute infection.\n* Radiation of measurable disease (except brain metastases)\n* Progressive brain metastases according to clinical or radiological criteria.\n* Brain metastases without prior radiation therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}